MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Autologous stem cell therapy (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MIDAS
- 06 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2022 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2024.
- 28 Mar 2022 Status changed from not yet recruiting to recruiting.